Merck & Company Inc. Common Stock (new) (MRK) exhibits 74.8% gross margins and 20.7% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 15.3x enterprise multiple and 6.6% implied options volatility.
Sustained 74.8% gross profitability converts into 34.3% operating margin and 20.7% ROIC, outpacing sector cost of capital.
ROIC: 20.7% // GM: 74.8%YoY revenue trajectory of +1.3% paired with 3.42% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +1.3% // FCF YLD: 3.42%Altman Z-Score of 5.19 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 5.19 // F-SCORE: 7/9Trading at 19.8x trailing P/E (18.4x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 19.8x // EV/EBITDA: 15.3xOptions market prices a ±6.6% implied move with a 0.78 put/call ratio around $143.00 max pain.
IMPL MOVE: ±6.6% // P/C: 0.78Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 28.1% net margins.
NET MARGIN: 28.1% // D/E: 0.89x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for MRK & activate live FRED threshold breach alerts.